For Your Rosacea Patients with Inflammatory Lesions

Time to surface

Prescribe the topical that helps them get clearer faster and longer 1, 2, a

Explore the Proposed Dual MOA of Ivermectin3-6
See the Superior Efficacy of Metrocream (Metronidazole) Topical Cream, 0.75%1,2
Learn about the Highly Tolerable Safety Profile1,2
Not an actual patient
Explore the Proposed Dual MOA of Ivermectin3-6
See the Superior Efficacy of Metrocream (Metronidazole) Topical Cream, 0.75%1,2
Learn about the Highly Tolerable Safety Profile1,2

aA phase 3, investigator-blinded, multicenter, randomized, parallel-group study comparing the efficacy and safety of Soolantra® (ivermectin) Cream, 1% once daily with MetroCream® (metronidazole) Topical Cream, 0.75% twice daily in 962 subjects aged 18 years and older with moderate to severe papulopustular rosacea (Investigator’s Global Assessment [IGA] score of 3 or 4) over a 16-week treatment period (Part A). A total of 757 successfully treated subjects, rated clear or almost clear (IGA score of 0 or 1), continued to the 36-week extension evaluating relapse after a treatment-free period (Part B).1,2

In Part B, subjects were followed every 4 weeks for up to 36 additional weeks (Weeks 16-52). If relapse (defined as IGA score of ≥2 [mild, moderate, or severe]) occurred, subjects were re-treated with the same treatment they had received during the initial 16-week study (Part A). Re-treatment was stopped when subject(s) achieved an IGA of ≤1 (clear or almost clear), with a maximum duration of re-treatment of 16 consecutive weeks to mimic the Part A treatment duration. Several re-treatment periods were permitted.2